Biovail and Alexza to Develop Inhaled Antipsychotic
By Taskin Ahmed
Pharma Deals Review: Vol 2010 Issue 2 (Table of Contents)
Published: 17 Feb-2010
DOI: 10.3833/pdr.v2010.i2.1314 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Biovail and Alexza Pharmaceuticals have signed a collaboration deal to develop and commercialise a promising late-stage central nervous system drug, AZ-004, for the treatment of agitation in schizophrenia and bipolar disorder patients...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018